Oncolytic virus experts at Replimune reload with $200M loan as biotech collects clinical data

A generally gloomy public market hasn’t stopped biotechs with big clinical plans from raking in the cash — either through stock offerings or loans.

Replimune is taking the latter route, inking a deal to borrow $200 million from Hercules Capital over the next five years in multiple tranches.